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A frequent complication in colorectal cancer (CRC) is
regeneration of the tumor after therapy. Here, we
report that a gene signature specific for adult intes-
tinal stem cells (ISCs) predicts disease relapse in
CRC patients. ISCs are marked by high expression
of the EphB2 receptor, which becomes gradually
silenced as cells differentiate. Using EphB2 and the
ISCmarker Lgr5, we have FACS-purified and profiled
mouse ISCs, crypt proliferative progenitors, and late
transient amplifying cells to define a gene program
specific for normal ISCs. Furthermore, we discov-
ered that ISC-specific genes identify a stem-like
cell population positioned at the bottom of tumor
structures reminiscent of crypts. EphB2 sorted ISC-
like tumor cells display robust tumor-initiating
capacity in immunodeficient mice as well as long-
term self-renewal potential. Taken together, our
data suggest that the ISC program defines a cancer
stem cell niche within colorectal tumors and plays
a central role in CRC relapse.
INTRODUCTION
Tissue regeneration in the intestine is ultimately sustained by
intestinal stem cells (ISCs) that reside at the base of mucosal
invaginations called crypts (Figure 1A). The progeny of ISCs,
termed transient amplifying (TA) cells, is expanded through
several rounds of mitosis while it migrates upwards along the
crypt axis. Close to the intestinal lumen, TA cells undergo cell-
cycle arrest and terminal differentiation. Stem cells of the mouse
small intestine (Barker et al., 2007), colon (Barker et al., 2007),and stomach (Barker et al., 2010) can be identified by the
specific expression of Lgr5, a G protein-coupled receptor of
unknown function. Lgr5+ ISCs are long lived, proliferate continu-
ously, and generate all cell types present in the gut. The onset of
intestinal tumorigenesis is driven in most cases by activating
mutations in the Wnt signaling pathway. Mouse Lgr5+ cells
give rise to intestinal tumors with higher efficiency than other
intestinal epithelial cell populations upon mutational activation
of the Wnt pathway (Barker et al., 2008). This observation
suggests that ISCs represent the cell of origin for colorectal
cancer (CRC).
CRC is the second cause of death by cancer. The current ther-
apeutic strategy for most CRC patients includes surgical resec-
tion of the tumor and chemotherapeutic treatment. After curative
therapy, a large proportion of CRC patients remain clinically
free of disease for months or years. Yet, after such period of
remission, cancer recurs in 30%–50% of all cases, generally in
the form of metastasis. The risk of cancer recurrence is linked
to the stage of the disease at the time of diagnosis (American
Joint Cancer Committee [AJCC] staging system). Most Stage I
CRC patients (95%–98%) will not develop recurrent cancer,
whereas 20%–25% of Stage II and 40%–50% of Stage III CRC
patients will experience disease relapse upon treatment.
Although a large proportion of deaths by CRC are caused by
recurrent tumors, the biological basis for disease relapse
remains unknown. Cancer relapse is caused by isolated tumor
cells that disseminated prior to resection of the primary tumor
and that resisted chemotherapeutic treatments. In some
patients, resilient cancer cells eventually resume growth and
regenerate a new tumor mass.
Recent studies have evidenced that not all cell populations
present in primary CRCs are capable of regenerating a tumor
as isolated entities. CRCs contain subsets of cells that can effec-
tively propagate the disease when implanted in an immunodefi-
cient host. These cells, termed tumor-initiating cells, can be
identified by the expression of surface markers such as cd133Cell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc. 511
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Figure 1. Isolation of Mouse Intestinal Epithelial Cell Populations According to EphB2 Expression
(A) IHC on mouse small intestine demonstrated maximum EphB2 expression in crypt base columnar cells (black arrowheads).
(B) Flow cytometry of crypt cells stained for EphB2 identified four distinct populations displaying different EphB2 cell surface levels (high, medium, low, and nega-
tive). Each cell population was sorted after gating for EpCAM+ staining (right panel) to ensure epithelial identity.
(C) qPCR analysis of stem cell, proliferation or differentiation markers.
(D–F) Phase contrast microscopy representative images taken at different time points document organoid growth from single-sorted EphB2hi cells. (E) Quanti-
fication of mature organoid formation from equal numbers of freshly isolated mouse EphB2-single cells. Two different experiments are shown.
(G–K) Organoids derived from single crypt units cultured for 1 month were stained for (G) MKI67 (proliferation), (H) Krt20 (pan-differentiation), (I) Lectin (Paneth
cells, granular apical staining), (J) Chromogranin A (enteroendocrine cells), or (K) Muc2 (Goblet cells). Empty arrowheads, crypt-like structures; white arrows,
differentiated cells. Counterstain, DAPI (violet).
(L) Validation of ISC-restricted expression of 3 genes from the EphB2hi-derived ISC signature by in situ hybridization.
See also Figure S1 and Table S1.
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Intestinal Stem-like Cells in Colorectal Cancer Relapse(O’Brien et al., 2007; Ricci-Vitiani et al., 2007) or cd44 (Dalerba
et al., 2007). Cd133+ or cd44+ cell populations represent a partic-
ular subset of aggressive CRC cells. In addition, some indirect
evidences suggest a connection between tumor-initiating cells
and ISCs. In particular, cd133 and cd44 are expressed in the
proliferative compartment of normal crypts (progenitors and
ISCs) (Snippert et al., 2009; Zeilstra et al., 2008). Also, purified
cd133+ tumor-initiating cells can be expanded in vitro as an
undifferentiated population that upon xenotransplantation
generates tumors that contain differentiated-like cells (Vermeu-
len et al., 2008). Despite these suggestive observations, a rela-
tionship between ISCs and cd133+/cd44+ tumor cells remains
speculative. Also, there is lack of evidence supporting a role of
tumor-initiating cells in cancer recurrence.512 Cell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc.Genes transcriptionally regulated by the Wnt pathway in the
intestinal epithelium are expressed with patterns ranging from
restricted expression to ISCs (e.g., Lgr5) to broad expression
in proliferative cells (e.g., Myc) (Van der Flier et al., 2007). One
of such Wnt target genes, the receptor tyrosine kinase EphB2,
is expressed in a decreasing gradient from the crypt base toward
the differentiated cell compartment (Batlle et al., 2002). EphB
activity is required to establish the position of the different cell
types in the crypts as mice mutant for EphB2, EphB3 (Batlle
et al., 2002), or their ligand ephrin-B1 (Cortina et al., 2007) display
defects in intestinal cell compartmentalization. Here, we take
advantage of EphB2 graded expression to purify and obtain
the expression profiles of ISCs and other crypt cell types. We
discover that expression of ISC-specific genes associates with
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Intestinal Stem-like Cells in Colorectal Cancer Relapsethe risk of developing recurrent CRC. Furthermore, paralleling
the results in normal crypts, the graded expression of EphB2 in
CRCs identifies tumor cell populations displaying ISC-like or
differentiated-like phenotypes.
RESULTS
Purification and Expression Profiling of ISCs and Other
Crypt Cell Types
The transcriptional profiles of the different cell types present in
the intestinal epithelium remain essentially uncharacterized,
which precludes an in-depth analysis of intestinal cell type-
specific gene program expression in CRC. We developed
a cell isolation method based on surface expression of EphB2,
which is expressed following a decreasing gradient from the
crypt base (Figure 1A). ISCs (i.e., crypt base columnar cells)
showed highest expression of membrane EphB2 (Figure 1A,
black arrowheads), whereas TA cells progressively decreased
EphB2 protein levels as they migrated toward the surface. Differ-
entiated cells in the villus and Paneth cells were negative for
EphB2 expression (Batlle et al., 2002). We stained suspensions
of disaggregated mouse intestinal cells with a monoclonal anti-
body directed against the extracellular domain of EphB2 (Mao
et al., 2004), and by FACS, we isolated epithelial cells (EpCAM+,
cd45, cd31, cd11b) displaying different EphB2 surface
expression (Figure 1B). Analysis ofmarker genes revealed similar
levels of Ki67, Myc, FoxM1, (Figure 1C) and other genes charac-
teristic of proliferating cells in EphB2hi and EphB2med cell
subpopulations (Figure S1 available online). However, EphB2hi
cells expressed around 5-fold higher levels of ISC-specific genes
Lgr5 (Barker et al., 2007), Ascl2 (van der Flier et al., 2009), and
Olfm4 (van der Flier et al., 2009) (Figure 1C). These results
suggest that the EphB2hi cell population is enriched in ISCs,
whereas EphB2med cells correspond mainly to crypt TA cells.
To test the functionality of each crypt cell population, freshly
isolated cells from mouse small intestine were cultured in condi-
tions that mimic the intestinal stem cell niche as previously
described (Sato et al., 2009). Single cells expressing high or
medium levels of EphB2 developed into complex multicellular
3D structures (Figure 1D). These in vitro organoids recreated
the organization of the intestinal epithelium, including the pres-
ence of multiple crypt-like structures (Figures 1D and 1F, arrow-
heads) distributed around a central lumen. EphB2hi cells showed
3- to 5-fold higher efficiency than EphB2med cells in the formation
of intestinal organoids (Figure 1E). This result parallels the enrich-
ment in ISC marker gene expression between EphB2hi and
EphB2med populations shown in Figure 1C. On the contrary,
EphB2lo and EphB2neg cells never grew (Figure 1E). Organoids
derived from single EphB2hi cells displayed proliferative Ki67+
cells within crypt-like evaginations (Figure 1G, empty arrow-
heads) and cell-cycle-arrested Krt20+ differentiated cells form-
ing large lumens (Figure 1H, arrows). Importantly, staining for
lineage-specific markers revealed the presence of all mature
intestinal cell types (Figures 1I–1K). Organoids were expanded
by mechanical disaggregation every 4 to 5 days over a 2 month
period without decrease in growth rates. The efficiency of orga-
noid generation from isolated EphB2hi cells was in the range of
0.5%–1%, similar to that obtained from Lgr5-GFPhi cells in our
laboratory (1%–2%; data not shown) and slightly lower thanreported before (Sato et al., 2009). Overall, these observations
support the idea that the EphB2hi cell population is enriched
in ISCs.
Gene Expression Signatures that Define ISCs,
Proliferative Cells, and Late TA Cells
By microarray analysis, we identified the global expression
profile of EphB2hi ISCs. We selected probe sets enriched at least
2-fold in EphB2hi compared with EphB2med cells, and that were
further downregulated in EphB2lo cells. Only 71 probes (54 anno-
tated genes) passed this stringent criterion (Table S1), including
the previously described ISC-specific genes Lgr5 (Barker et al.,
2007) and Ascl2 (van der Flier et al., 2009). The expression of
several randomly selected genes from this list (Smoc2, Pcdh8,
and Igfbp4) was restricted to small, wedge-like cells intermingled
with Paneth cells at the crypt-bottom most positions (Figure 1L;
data not shown). This pattern is characteristic of Lgr5+ cells
(Barker et al., 2007), implying that these three genes represent
new ISC-specific markers. To broaden this analysis, we
analyzed the expression of the EphB2hi ISC signature in Lgr5-
GFP knockin mice (Barker et al., 2007). The vast majority
(98%) of genes contained in the EphB2hi ISC gene expression
signature were upregulated (>1.5-fold, p < 0.05) in Lgr5-GFPhi
cells relative to Lgr5-GFPlo cells (Figures S2A–S2C) (Barker
et al., 2007). Of note, the EphB2hi ISC gene signature did not
contain core pluripotency genes (i.e., oct4, sox2, nanog, klf4)
or the Myc-driven gene module characteristic of ESCs (Kim
et al., 2010). It was not enriched in genes directly involved in
proliferation owing to equal levels in ISCs and TA cells (see
below).
We also established the gene program that defines the prolif-
eration status of crypt cells by selecting probes expressed at
equivalent levels in EphB2hi and EphB2med cells that were
silenced in EphB2lo cells (Table S1). This gene module was en-
riched in known mediators of DNA replication, mitosis, DNA-
damage repair, and proliferation (Figure 1C and Figure S1).
Genes with higher expression levels in EphB2lo compared to
EphB2med cells that were further downregulated in EphB2hi
subpopulation constituted the gene expression signature of
late progenitor cells (Table S1). This set contained several well-
established markers of intestinal differentiation such as Krt20,
Anpep, or Ada (Figure 1C, Figure S1 and Table S1).
Aggressive CRCs Are Enriched in ISC Gene Expression
Each gene expression signature described above was instru-
mental to investigate whether the global transcriptional profile
of human CRCs resembled that of any particular crypt cell
type. Crypt proliferation genes were overexpressed in all CRCs
compared with normal tissue (Figure 2A). Remarkably, 38% of
the genes from the EphB2hi ISC gene programwere also overex-
pressed in CRCs, including the bona fide ISC markers Lgr5 and
Ascl2 (Figure 2B) (average fold change >1.5, p< 0.05). The signa-
ture of late TA cells was silenced overall (Figure 2A), and Krt20
and other markers of intestinal differentiation were downregu-
lated relative to normal tissue (Figure 2B and data not shown).
We next investigated the association of each crypt cell gene-
expression signature with clinical progression of CRC. We
selected for analysis a representative pooled cohort of 340
primary colon cancer patients treated at three different hospitalsCell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc. 513
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Figure 2. Aggressive CRCs Are Enriched in ISC Gene Expression
(A) Unsupervised hierarchical clustering analysis of transcriptional profiles of normal mucosa (NM) and CRC samples according to different crypt expression
signatures.
(B) Plots depict relative expression levels of Lgr5, Ascl2, Ki67 and Krt20 in NM and CRC samples according to microarray measurements.
(C,D) GSEA results for the EphB2hi ISC, Proliferation and Late TA signatures in Stage III-IV compared to Stage I-II colon cancers (C) or in well-differentiated versus
poorly differentiated colon cancers (D). ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.
See also Figure S2 and Tables S2, S3, and S4.
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Analysis (GSEA) revealed that the expression of EphB2-ISC
genes was strongly associated with metastatic compared with
nonmetastatic colon cancer (Figure 2C; Stage IV versus the
rest, FDR < 0.0003; data not shown). In addition, the EphB2-
ISC and Proliferation signatures were enriched in poorly differen-
tiated tumors compared to more benign well-differentiated
CRCs (Figure 2D).
To strengthen the above observations, we derived an inde-
pendent ISC expression signature from Lgr5-GFP cells. We
selected those probes more acutely upregulated in Lgr5-GFPhi
versus Lgr5-GFPlo cells (>3 fold, p < 0.05, Table S1). 54% of
the genes contained in the Lgr5-GFPhi signature were not repre-
sented in the EphB2hi ISC signature (Figure S2D) due to the
different cut-offs used to define both gene lists. Like for EphB2hi
genes, the Lgr5-GFPhi signature was highly enriched in meta-
static colon cancer (Figure S2E; Stage IV versus the rest;
FDR < 1 3 108; data not shown) as well as in poorly differenti-
ated compared with well-differentiated tumors (Figure S2E).
Altogether, these results suggest that a distinctive feature of
aggressive colon cancers is high expression of an ISC-like
gene program.Expression of ISC-Specific Genes Predicts Disease
Relapse in CRC Patients
GSEA also revealed that the EphB2-derived ISC signature was
highly enriched in genes that positively predicted the relative
risk of developing recurrent cancer upon intended curative
therapy (FDR < 13 108; Figure 3A). We used ISC gene expres-
sion levels to stratify CRC patients into three groups (Figure 3B).
Patients bearing primary CRCs with high average expression of
ISC genes had a relative risk of relapse 10-fold higher than those
with low levels (p < 0.0001). The EphB2-ISC medium expression
group displayed an intermediate risk (medium versus low; HR =
6.28; p = 0.0182). Remarkably, the EphB2-ISC low group
remained virtually disease-free during 10 years of follow-up
with only one early recurrent cancer (Figure 3B). The EphB2-
ISC signature expression displayed an incremental and approx-
imately linear effect on the risk of recurrence (Figure 3C; linearity
test, p = 0.5). Multivariate analysis using the Cox Proportional
Hazards Model demonstrated that the EphB2-ISC signature is
a predictor of disease relapse independent of AJCC staging
(Figure 3D). We obtained equivalent results for the Lgr5-ISC
signature (Figure S2H).
We noticed that the EphB2- and Lgr5-derived ISC signatures
predicted relapse with borderline significance in the multivariate
analysis (p = 0.04 and p = 0.02, respectively; Figure 3D and Fig-
ure S2H). Yet, both ISC signatures performed better to identify
CRC relapse occurring later than 2 years after curative therapy
(Figure 3B and Figure S2F, dashed lines). GSEA confirmed that
both ISC signatures were enriched in genes associated with
late (>2 years) compared with early colon cancer relapses
(Figure 3E and Figure S2I). Remarkably, multivariate analysis re-
vealed that EphB2-ISC (Figure 3F) and Lgr5-ISC (Figure S2J)
signatures outperformed the AJCC staging system in the identi-
fication of relapses occurring after 2 years of treatment. Thus,
late recurrent tumors appear to arise preferentially from CRCs
that expressed high levels of ISC genes.The gene expression signature obtained from late TA
cells was enriched in genes that predicted no relapse over
follow-up, albeit with borderline statistical significance (FDR =
0.03; Figure 3A). In addition, several well-established markers
of intestinal differentiation associated inversely with tumor
recurrence, including MUC2 (p = 0.024; HR = 1.37), TFF3
(p = 0.011; HR = 1.38), MATH1 (p = 0.0001; HR = 1.54),
CDX2 (p = 0.0005; HR = 1.54), or Villin (p = 0.02;
HR = 1.31). GSEA also demonstrated that the crypt prolif-
eration signature was inversely associated with disease
relapse (Figure 3A) as previously reported (Anjomshoaa et al.,
2008). This observation reinforces the notion that ISC
and proliferation genes measure independent features of
the tumor.Humanized Colon Crypt ISC Signatures Identify
Recurrent CRCs
The gene-expression signatures used in this study were
obtained from mouse intestinal cells. We reason that genes
involved in essential functions for crypt cells must be largely
conserved between human and rodents. Yet, to rule out the
possibility that the use of mouse-derived gene lists may impose
artifacts in the clinical association studies, we analyzed their
overall expression patterns in human colon mucosa. We interro-
gated a publicly available data set of transcriptomic profiles of
normal human colon mucosa in which the top crypt and bottom
compartments were microdissected and analyzed separately
(Kosinski et al., 2007). GSEA showed that EphB2-ISC, Lgr5-
ISC, and Proliferation signatures were largely enriched in crypt
human bottom compared to top region compartments, whereas
the Late TA signature followed the reverse pattern (Figure 4B).
Thus, to a large extent, mouse-derived signatures used in this
study are expressed by human colon crypts with equivalent
patterns. Using the expression profiles of human colon crypts
as filters, we excluded from each mouse crypt-derived cell
signature those genes that were not differentially expressed
between human colon crypt-bottom and crypt-top compart-
ments (see Experimental Procedures). The resulting ‘‘human-
ized’’ gene lists (Table S5) associated with disease progression
with equivalent strength and specificity than the unrefined
mouse crypt-derived gene lists (Figures 4C–4F and Figure S3).
In particular, Hu-EphB2-ISC and Hu-Lgr5-ISC signatures
were enriched in metastatic CRC (Stage IV versus the rest, Hu-
EphB2-ISC; FDR = 0.04 and Hu-Lgr5-ISC; FDR < 1016, data
not shown) as well as in recurrent tumors (Figure 4C and Fig-
ure S3A). Analogous to the signature of mouse crypt proliferative
cells, theHu-Proliferation signaturewas enriched in nonrecurrent
CRCs (FDR < 1016, data not shown). In addition, GSEA
confirmed a further enrichment of Hu-ISC signatures in tumors
that will relapse relatively late (>2 years) (Figure 4D and Fig-
ure S3D). Both Hu-EphB2-ISC and Hu-Lgr5-ISC signatures had
approximately linear effect on the risk of recurrence (Figure 4E
and Figure S3B). Multivariate analysis using the Cox Proportional
Hazards Model demonstrates that the power of the humanized
ISC signatures to predict relapse is, to a large extent, indepen-
dent of AJCC staging (Figure 4F and Figure S3C and S3E). Over-
all, these results strengthen the specificity of the association of
the ISC expression programwith the clinical progression of CRC.Cell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc. 515
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Figure 3. Expression of ISC Genes Predict CRC Relapse
(A) GSEA results for crypt signatures in recurrent (Rec) versus nonrecurrent (No Rec) CRC samples.
(B) Kaplan-Meier representation of recurrence-free survival probability over time for patients bearing colon cancers with average high, medium, or low expression
of EphB2-derived ISC signature.
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Figure 4. Humanized ISC Signatures Identify Recurrent CRCs
(A) Representation of a normal colonic crypt.
(B) GSEA of each mouse expression signature in human colon crypt-top versus crypt-bottom regions.
(C) GSEA for ‘‘humanized’’ Hu-EphB2-ISC signature comparing recurrent (Rec) with nonrecurrent (No Rec) colon cancers.
(D) GSEA for Hu-EphB2-ISC signature comparing tumors that recurred 2 years or later after therapy (late) with nonrecurrent tumors (No Rec).
(E) log-Hazard Ratio (HR) of recurrence as a smooth function (penalized quartic splines) of the average Hu-EphB2-ISC expression. Dashed lines, 95% confidence
intervals. The effect of average Hu-EphB2-ISC score on the recurrence log-hazard ratio did not deviate significantly from linearity (linearity test; p < 0.5).
(F) Upper table: multivariate analysis using Cox Proportional Hazards Model to assess dependency of different tumor variables in the prediction of CRC relapse.
Hu-EphB2-ISC expression modeled as a linear effect, as supported by (E). Lower table: multivariate analysis of Hu-EphB2-ISC signature for late CRC relapse
(>2 years).
See also Figures S2 and S3 and Tables S2, S3, S4, and S5.
Cell Stem Cell
Intestinal Stem-like Cells in Colorectal Cancer RelapseColorectal Cancers Contain Cells with Either Intestinal
Stem Cell-like or Differentiated-like Phenotypes
The above observations indicate that most aggressive CRCs
express high levels of ISC-specific genes. This phenomenon is
associated to the ability of tumor cells to recur after therapy.
We next sought to understand whether the ISC program was
homogenously expressed by all tumor cells or restricted to(C) log-Hazard Ratio (HR) of recurrence as a smooth function of the average ISC e
The effect of average EphB2-ISC score on the recurrence log-hazard ratio did n
(D)Multivariate analysis using Cox Proportional HazardsModel to assess depende
sion modeled as a linear effect, as supported by (C). We report HR and standard
(E) GSEA of EphB2-ISC signature in late-recurrent (>2 years) versus early-recurre
into consideration.
(F) Multivariate analysis of EphB2-ISC signature for late CRC relapse (>2 years).
those relapsing >2 years after intended curative therapy.
See also Figure S2 and Tables S2, S3 and S4.specific subpopulations. We used Lgr5 as a surrogate marker
to identify the localization of tumor cells with ISC-like phenotype.
By in situ hybridization, we detected Lgr5 mRNA at the base of
human colonic crypts (Figure 5B) as well as in a large proportion
of tumor samples fromCRCpatients (Figure 5F). Lgr5 expression
was heterogeneous among different tumors. The frequency of
positive cells ranged from <1% to 95% (Figure 5F), and stainingxpression (penalized quartic splines). Dashed lines, 95% confidence intervals.
ot deviate significantly from linearity (linearity test; p = 0.5).
ncy of different tumor variables in the prediction of cancer relapse. ISC expres-
ized HR for +1 SD increase in ISC expression.
nt (%2 years) CRC patients. For this analysis, only recurrent tumors were taken
In this analysis, patients that did not relapse over follow-up were compared to
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Figure 5. CRCs Retain an Organization that Resembles that of Normal Colon Tissue
(A) Representation of a normal colonic crypt. ISCs (in red) are located at the crypt bottommost positions.
(B–E) Analysis of expression domains of Lgr5 mRNA and Krt20 protein in serial sections of human normal colon mucosa (B and C) and CRC (D and E). Red arrow-
heads, Lgr5+ cells; black arrowheads, Krt20+ cells. Insets: high magnification images of a crypt-like structure, depicted by a dashed line. Str, stroma; Lu, tumor
gland lumens.
(F) Frequency of Lgr5+, Krt20+, or double-negative (Lgr5Krt20) cells in the CRC samples analyzed (n = 32).
(G) Representation of CRC organization.
(H) Analysis of Lgr5 mRNA and KRT20 protein in serial tissue sections of a representative primary CRC and its corresponding liver metastasis.
See also Figure S4.
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Intestinal Stem-like Cells in Colorectal Cancer Relapsewas restricted to cell clusters dispersed throughout the tumor
mass (red arrowheads in Figure 5D and Figure S4). Commonly,
Lgr5+ cells localized within the most basal tumor cell layers.
In tumor regions that displayed glandular organization, Lgr5+
cells resided at sites where the tumor epithelium invaginates
into the surrounding stroma (dotted lines in Figure 5D and Fig-518 Cell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc.ure S4). Remarkably, the morphology of these invaginations
was reminiscent of that of normal colon crypts. As exemplified
in Figure 5D, some CRCs were constituted by abundant crypt-
like structures arrayed around large lumens. Other CRCs con-
tained individual Lgr5+ crypts dispersed throughout the tumor
mass (examples in Figure S4). Of note, we could not detect the
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Intestinal Stem-like Cells in Colorectal Cancer Relapseexpression of Lgr5 in one-third of the samples analyzed (Fig-
ure 5F) owing to low sensitivity of ISH technique on archival
material. This subset included most poorly differentiated CRCs
that consistently showed low levels of Lgr5 (data not shown)
even though they were, overall, enriched in expression of ISC-
specific genes (Figure 2D and Figure S2E).
We also investigated the expression of intestinal differentiation
markers in CRC. Krt20 codifies for a cytokeratine whose levels
increase sharply in late progenitor and differentiated cells of
normal crypts (Figure 5C, black arrowheads). Interestingly, we
observed that the expression patterns of Krt20 and Lgr5 in
CRC were mutually exclusive. Staining of serial tumor sections
demonstrated that Lgr5+ cells were devoid of Krt20 staining,
whereas neighboring Krt20+ cells lacked Lgr5 expression (black
arrowheads in Figure 5E and Figure S4). This complementary
expression pattern was found in all Lgr5+ tumors analyzed.
In tumors with glandular growth patterns, Lgr5 mRNA was
detected at the base of crypt-like units, whereas Krt20+ cells
resided near luminal spaces (insets in Figures 5D and 5E).
Some samples also contained double-negative cells positioned
between Lgr5+ and Krt20+ cells (white arrowheads in Figure 5H
and Figure S4B), suggesting the existence of tumor cells with
intermediate phenotypes. Double Lgr5/Krt20-positive tumor
cells were rare (<1%) and only present in 8% of samples (data
not shown). Twelve out of 14 CRC liver metastases analyzed
also contained Lgr5+ tumor cells adjacent to Krt20+ cells that
recreated the organization of the primary tumor. Metastatic
Lgr5+ CRC cells were also located at the base of crypt-like struc-
tures (Figure 5H, red arrowheads) with Krt20+ tumor cells occu-
pying luminal positions (Figure 5H, black arrowheads). From
the limited number of marker genes analyzed, we tentatively
concluded that a large proportion of CRCs contain cells with
two mutually exclusive phenotypes: an ISC-like or a differenti-
ated cell-like phenotype (Figure 5G).
EphB2 Is a Surface Marker for ISC-like Tumor Cells
We then investigated whether EphB2 expression could distin-
guish between ISC-like and differentiated-like cells in CRCs as
it does in the normal intestinal mucosa. Figures 6A–6C and Fig-
ure S5 show the expression patterns of EphB2, Lgr5, and Krt20
in serial sections of representative CRCs. Most CRCs were
composed of cell clusters expressing heterogeneous EphB2
levels ranging from highly positive, to intermediate, to completely
negative (Figure 6A, red, blue, and green arrowheads, respec-
tively). In the vast majority of tumors analyzed (n = 30), prominent
EphB2 staining coincided with Lgr5 expression (Figures 6A and
6B, red arrowheads, and Figure S5). In glandular tumors, EphB2
and Lgr5 labeled the base of crypt-like structures that grew
embedded into the tumor stroma (Figure 6A and 6B, dashed
lines). On the contrary, the majority of Krt20+ tumor cells were
EphB2lo or EphB2neg in all tumors (Figures 6A and 6C, green
arrowheads, and Figure S5). Of note, EphB2 was silenced in
areas of high grade as we previously reported (Batlle et al.,
2005). Commonly, these areas also showed low levels of Lgr5
expression (data not shown).
We also analyzed the possibility that markers of tumor initi-
ating cells (TICs) (i.e., cd44 and cd133) recognize ISC-like cells
in CRCs. Cd44 and Lgr5 expression domains overlapped
largely in most tumors (7 out 9 samples analyzed) (Figures S6Aand S6B), yet Krt20+ cells were also partially included in the
cd44+ domain in two-thirds of the samples (Figure S6). Cd133
antibody stained the apical membrane of luminal tumor cells
whereas, in most cases, ISC-like cells were located in basal
positions (Figures S6G and S6H). This localization is consistent
with that described previously (Shmelkov et al., 2008). However,
it is important to mention that cd133 antibodies used for
FACS recognize a conformational epitope in TICs (Kemper
et al., 2010).
To strengthen the link between the EphB2hi tumor cell popula-
tion and the ISC-like phenotype, we analyzed EphB2 surface
expression by flow cytometry on primary CRC biopsies (Fig-
ure 6D). In most tumors, epithelial cells (EpCAM+) were hetero-
geneous regarding EphB2 surface abundance with relative
levels ranging from 1 to 104 (Figure 6D). This distribution resem-
bled that of the normal intestinal epithelium, though different
EphB2hi versus EphB2lo cell ratios characterized each tumor.
We purified tumor epithelial cells expressing either the highest
EphB2 relative levels (top 10%–15% brightest cells) or display-
ing low/negative EphB2 surface expression. Consistent with
the observation on tissue sections, in 5 out of 6 samples
analyzed, EphB2hi tumor cells expressed higher levels of ISC-
specific genes Lgr5 and Ascl2 than EphB2lo/EphB2neg cells
(Figure 6D). On the contrary, EphB2lo/ EphB2neg cells were char-
acterized by increased expression of Krt20 as well as of Krt17,
another marker of mature colonic cells (Figure 6D). Combined
immunophenotyping with EphB2 and cd44 antibodies showed
that cd44hi cell populations were enriched in EphB2hi cells in
all samples (Figure S7A). Still, EphB2 surface expression distin-
guished between ISC-like and differentiated-like cells within
the cd44hi population (Figure S7B). These results are in agree-
ment with the staining patterns observed in tissue sections and
suggest that cd44 marks ISC-like cells albeit with lower speci-
ficity than EphB2.
ISC-like Cells Are Tumor-Initiating Cells and Display
Self-Renewal and Differentiation Capacity
We then sought to determine the tumorigenic potential of ISC-
like or differentiated-like tumor cells. As a proof of principle, we
purified epithelial tumor cells (EpCAM+) expressing high,
medium, or low surface EphB2 levels (Figure 7A) from a stage
IV CRC. The relative expression of ISC marker genes Lgr5,
Ascl2, Olfm4, and Smoc2 declined from EphB2hi to EphB2lo
populations (Figure 7B). Conversely, expression of pan-intestinal
differentiation markers Krt20, Krt17 and Ceacam5 was highest
in EphB2lo cells and decreased progressively in EphB2med
and EphB2hi cells. Importantly, the three EphB2 populations
expressed equal levels of proliferation markers such as Ki67
(Figure 7B) and Myc (data not shown).
To test the tumor forming capacity of each EphB2-purified cell
population we performed subcutaneous injections into NOD/
Scidmice. The three tumor cell populations (EphB2hi, EphB2med,
and EphB2lo) showed equivalent viability after FACS measured
by propidium iodide and trypan blue exclusion (data not shown).
Figure 7C shows tumor-free survival plots for mouse cohorts
inoculated with different cell dosages. Mice that did not develop
tumors were followed over a period of at least 5 months.
EphB2hi, EphB2med, and EphB2lo cells inoculated in high
numbers (5000 cells) formed tumors with similar frequency andCell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc. 519
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Figure 6. EphB2 Identifies ISC-like Cells within Tumors
(A–C) EphB2 (A) and Krt20 (C) protein IHC, and Lgr5 mRNA ISH (B), in serial sections of a representative human CRC. Red arrowheads indicate Lgr5+/EphB2+/
Krt20 cells at the base of crypt-like units (dashed lines); green arrowheads indicate luminal Lgr5/EphB2/Krt20+ cells; blue arrowheads indicate tumor cells
with intermediate levels of EphB2. Str, stroma; Lu, tumor gland lumens.
(D) EphB2 FACS profiling and RT-qPCR of selected genes in EphB2 populations sorted from different primary tumor biopsies (T26, T27, and T30) or from different
primary tumors expanded one round as subcutaneous xenografts in immunodeficient mice (SP6, SP9, and SP14). ND, not determined.
See also Figures S5, S6, and S7.
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Intestinal Stem-like Cells in Colorectal Cancer Relapselatency. At lower dosages (1000 or 100 cells), EphB2hi cell pop-
ulation retained the capacity to generate tumors with high effi-
ciency whereas EphB2lo/EphB2neg cells displayed reduced or
null tumorigenic capacity. EphB2med cells showed an interme-
diate behavior. Applying the maximum-likelihood estimation
method of limiting dilutions assay, we calculated a frequency
of tumor initiating cells of 1 in 72 for EphB2hi, 1 in 610 for
EphB2med cells and 1 in 2751 for EphB2lo cells (Figure 7F). There-
fore, the enrichment in tumor initiating cells paralleled the
expression of ISC genes.
EphB2hi cells generated xenografts with histological patterns
that largely resembled the primary tumor including the presence
of EphB2hi, EphB2med, and EphB2lo cells (representative
example is shown in Figures 7D and 7E). Assessment of
EphB2 surface abundance by flow cytometry confirmed that
engrafted EphB2hi tumor cells gave rise to EphB2med and
EphB2lo populations (Figure 7D). Remarkably, the relative
expression levels of ISC, proliferation, and differentiation marker
genes in the three secondary EphB2 populations were analo-520 Cell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc.gous to those of the primary xenograft (Figure 7E). Thus, few
inoculated EphB2hi cells effectively propagated the disease in
immunodeficient hosts while restoring the patterns of ISC-like
and differentiated-like cells of the tumor of origin. To strengthen
this conclusion, we tested the tumorigenic potential of different
populations of secondary and tertiary EphB2hi-derived xeno-
grafts (Figure 7F). The frequency of tumor-initiating cells in
each secondary and tertiary cell population did not differ signifi-
cantly from that calculated in the tumor of origin (p > 0.05 for all
comparisons) (Figure 7F). We conclude that ISC-like tumor cells
hold high tumor-initiating potential as well as display long-term
self-renewal and differentiation capacity.
DISCUSSION
The association of stem cell genes with disease outcome in
several cancer types is widely accepted. This notion has spread
from studies that used expression signatures derived from
tumor-initiating cells (Glinsky et al., 2005). These signatures
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Figure 7. EphB2hi Cells Are Enriched in Tumor-Initiating Cells
(A) EphB2 antibodies reveal heterogeneous staining of tumor cells (left panel). Red, blue, and green arrowheads point to EphB2hi, EphB2med, and EphB2lo cells,
respectively. Viable EpCAM+ tumor cells (propidium iodide, central panel) were selected and sorted according to EphB2 expression levels (right panel).
(B) RT-qPCR of selected genes in tumor EphB2 populations.
(C) Subcutaneous growth of tumor EphB2 populations in NOD/Scid mice. 5000, 1000, and 100 cells were injected. Tumor growth was assessed over a 5 month
period.
(D) IHC and FACS analysis (as in A) of a representative secondary EphB2hi-derived xenograft.
(E) RT-qPCR of selected genes in secondary EphB2 populations purified from an EphB2hi-derived tumor.
(F) Estimated frequencies of tumor-initiating cells (TICs) in EphB2 populations derived from 1st, 2nd, and 3rd passage tumors arising from EphB2hi cells were not
significantly different (p > 0.05). Histogram, mean TIC frequency; error bars, SEM; *p < 0.05.
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Intestinal Stem-like Cells in Colorectal Cancer Relapsemay reflect the gene program of a particularly aggressive popu-
lation rather than that expressed by adult stem cells. On the other
hand, pluripotency genes expressed by embryonic stem cells
(ESCs) have also been generally correlated with poor prognosis
in cancer (Ben-Porath et al., 2008). Yet, the correlation of ESC
genes with cancer progression has been recently undermined
by the finding that a Myc-driven gene program rather than core
pluripotency genes accounts for similarities between ESCs and
cancer stem cells (Kim et al., 2010). Our work provides unequiv-
ocal evidence that the risk of developing recurrent CRC is
proportional to the expression in the primary tumor of a set of
genes specific of normal ISCs. This finding raises the possibility
that tumor cells require ISC-specific functions to effectively
regenerate cancer after therapy. The robust association of the
ISC signature with cases of late relapse favors the idea that
ISC genes endow long-term survival and regeneration potential
rather than immediate tissue colonization capacity. A recentwork by Di Fiore and colleagues correlates higher grading in
breast cancers with higher frequencies of cancer cells express-
ing a breast stem cell-like phenotype (Pece et al., 2010). Our
assessment of ISC gene expression levels may estimate both
the relative number of ISC-like cells within a given tumor as
well as the overexpression of particular ISC genes co-opted by
CRC cells.
The signature of crypt proliferation shows a strong but reverse
correlation with CRC recurrence. A similar association was
reported independently (Anjomshoaa et al., 2008), and it is in
sharp contrast to the results obtained for breast cancer where
a high proliferative index indicates poor prognosis (Anjomshoaa
et al., 2008). It remains to be determined whether high levels of
proliferation genes in CRC modify the efficacy of chemothera-
peutic drugs that target the cell division machinery. In any
case, a straight interpretation of this result is that the predictive
power of ISC genes for relapse does not stem from their role inCell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc. 521
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Intestinal Stem-like Cells in Colorectal Cancer Relapseproliferation. On the other hand, we found that expression of
several individual markers of intestinal differentiation in the
primary tumor associates with good prognosis. The late TA
signature is also enriched in genes that inversely predicted
disease relapse yet with borderline significance. We speculate
that this may be due to incomplete or aberrant expression of
the differentiation program by CRC cells.
In tumor tissue, ISC and differentiation programs are ex-
pressed with mutually exclusive patterns that resemble those
of the normal intestinal mucosa. We identify a subpopulation of
tumor cells with an ISC-like phenotype that localizes in close
proximity to cells that express intestinal differentiation genes.
In well- andmoderately differentiated CRCs, these two cell types
reside within defined structures reminiscent of intestinal crypts.
In healthy intestinal mucosa, high EphB2 levels mark cells at
the crypt base (i.e., ISCs), whereas the ISC progeny gradually
silences EphB2 expression as it migrates away from the stem
cell niche. The EphB2 expression gradient is required to
compartmentalize cell populations in different territories of the
healthy epithelium (Batlle et al., 2002). FACS analysis demon-
strates that CRCs display a graded expression of EphB2 remi-
niscent of that of intestinal crypts. ISC-like tumor cells are
EphB2hi and reside closer to the stroma whereas differenti-
ated-like cells are low or negative for EphB2 expression and
face the luminal sides of tumor glands. Thus, like in normal
epithelium, the identity and position of ISC-like and differenti-
ated-like cells within the tumor correlates with different EphB2
surface levels. This pattern is common to a large proportion of
CRCs except for poorly differentiated tumors that express low
EphB2 levels as we previously reported (Batlle et al., 2005).
Mouse colon tumors engineered to lack EphB signaling acquire
a nonglandular growth pattern characterized by loss of cell
polarity and an aggressive phenotype (Batlle et al., 2005; Cortina
et al., 2007). Thus, EphB2 silencing in ISC-like cells may
contribute to the loose architecture of poorly differentiated
CRCs. Besides the downregulation of EphB2, GSEA demon-
strates that poorly differentiated CRCs retain an overall ISC-
like phenotype compared with well-differentiated tumors. It
would be beneficial to identify additional ISC marker genes
that label the EphB2neg tumor stem cell population in poorly
differentiated CRCs.
A central question that arises from our observations is how the
ISC and differentiated programs aremaintained in CRC. A recent
report demonstrates that tumor cells grown in vitro as colono-
spheres display different amounts of b-catenin/Tcf signaling
that, in turn, regulate the expression of stem cell or differentiation
markers (Vermeulen et al., 2010). Also, in some CRCs, strongest
nuclear b-catenin accumulation corresponds to tumor cells posi-
tioned closer to the tumor stroma (Brabletz et al., 2001). This
localization is consistent with the Lgr5 expression domain
reported here. Thus, differential Wnt signaling may account for
the establishment of ISC-like or differentiated-like populations
in a subset of CRCs. Other pathways involved in the balancing
of the differentiation and stem cell programs in normal crypts
such as Notch or BMP signaling may potentially regulate the
relative numbers of ISC- and differentiated-like cells in tumors.
We have shown that primary tumors and metastasis share an
equivalent distribution of ISC-like and differentiated-like cell
populations. Apparently, the disseminated cell that propagates522 Cell Stem Cell 8, 511–524, May 6, 2011 ª2011 Elsevier Inc.the disease to the metastasic site reconstitutes the populations
and organization of the tumor of origin. ISC-like tumor cells are
candidates to represent tumor propagating cells in CRC as
they generate tumors in immunodeficient hosts with high effi-
ciency compared with differentiated-like cells. In addition,
tumors generated from ISC-like cells recapitulate the organiza-
tion of the tumor of origin. These two features parallel the self-
renewal and differentiation properties of normal ISCs. Our results
also indicate that the previously identified cd44+ tumor-initiating
cell population is partially enriched in ISC-like cells. Overall,
these discoveries strengthen the view of a hierarchical organiza-
tion of CRC cells similar to that present in normal crypts and
suggest that ISC-like cells are the tumor cell population that insti-
gates recurrent cancers.
EXPERIMENTAL PROCEDURES
Histological Procedures
Detailed protocols for Immunohistochemistry, in situ hybridization, and immu-
nofluorescence are provided in Supplemental Information.
Intestinal Crypt Cell Purification and In Vitro Growth
A detailed protocol for the purification of crypt cell types according to EphB2
expression is available in the Supplemental Information section. In vitro growth
of intestinal organoids and FACS purification of Lgr5-GFPhi or Lgr5-GFPlo cells
were performed as previously described (Sato et al., 2009).
Generation of Crypt Cell Gene-Expression Signatures
We measured gene-expression levels of three EphB2 selected populations
in two independent experiments using Affymetrix mouse4302 arrays. For a
detailed description of the statistical method to define each crypt expression
signature, please refer to Supplemental Information.
CRC Patient Gene Expression Data Sets and Association of Crypt
Expression Signatures with Clinical Outcome
At the moment of performing this study, there were six publicly available CRC
gene expression datasets annotated with clinical information in the Gene
Expression Omnibus at NCBI (GSE17538, GSE10402, GSE12945, GSE5206,
GSE12032 and GSE14333). We compared the robustness and accuracy of
these data sets (see Supplementary Information) and selected datasets
GSE17538 (Smith et al., 2010) and GSE14333 (Jorissen et al., 2009) for further
analysis. We combined both cohorts for a total of 340 unique CRC expression
profiles. For descriptive statistics as well as association of major clinical
progression parameters and clinical outcome for this cohort, please refer to
Supplemental Experimental Procedures and Tables S3 and S4. Detailed
descriptions of all statistical analysis employed in this manuscript are included
in Supplemental Information.
Analysis of Mouse Signatures in Human Colon Crypt Top
and Bottom Compartments
We used the GSE6894 dataset (Kosinski et al., 2007), which contains expres-
sion profiles of microdissected human colon crypt top and bottom compart-
ments (n = 9 pairs from different mucosa samples). We refined the ISC,
Lgr5, and proliferation signatures by selecting genes differentially expressed
in human colon crypts (crypt-bottom > crypt-top for EphB2-ISC, Lgr5-ISC,
and proliferation signatures and crypt-top > crypt-bottom for Late TA
genes, >1.5-fold in all cases).
Tumor Disaggregation and Sorting of EphB2 Cell Populations
and Assays of Tumor Initiation
Primary tumor samples were obtained from Hospital del Mar (Barcelona,
Spain) or Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). Detailed
protocols for tumor dissagregation and tumor cell purification are described
under Supplemental Experimental Procedures. Different EphB2-purified cell
fractions were injected s.c. into NOD/Scid mice. Tumor growth was monitored
Cell Stem Cell
Intestinal Stem-like Cells in Colorectal Cancer Relapseover 5 months. Frequency of tumor-initiating cells was estimated according to
published methods (Hu and Smyth, 2009).
ACCESSION NUMBERS
Microarray data are accessible at the Gene Expression Omnibus (GEO) data-
base under accession number GSE27605.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, five tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.stem.2011.02.020.
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